Calcium dobesilate (CLS 2210) protects the myocardium in early acute myocardial infarction: A preliminary randomized, double-blind, placebo-controlled study of its effects on biochemical markers

Laszlo Szlavy, I. Repa, Imre Lengyel, Laszlo Lamboy

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

To determine the effect of calcium dobesilate CLS 2210) on biochemical markers of acute myocardial nfarction, and thereby assess its action in limiting myocardial necrosis, this compound was administered intravenously by a randomized, double-blind technique to 23 of 41 patients suffering their first infarction. The remaining 18 patients received a placebo. Administration was egun within 3 h of onset of symptoms and continued for 2 h. Before and during treatment, blood samples were aken for measurement of the serum activity of creatine inase and its isoenzyme MB, and the serum and urinary oncentrations of myoglobin and glycosaminoglycans. Serum creatine kinase and serum and urinary myoglobin vere significantly lower in the CLS 2210-treated patients than in the placebo patients throughout the 72 h (p = 0.01, 0.005, and 0.004, respectively). Serum creatine kinase MB and serum glycosaminoglycan in the CLS 2210 patients were initially higher than in the controls, but fell below the control levels between the 40th and 55th hours (p = 0.89 and 0.02, respectively). The glycosaminoglycan urinary concentrations alone were higher in the CLS 2210 group than in the placebo group throughout (p = 0.0005). These findings suggest that CLS 2210 reduces myocardial infarct size in human subjects, as it is already known to do in animals.

Original languageEnglish
Pages (from-to)89-95
Number of pages7
JournalJournal of Cardiovascular Pharmacology
Volume15
Issue number1
Publication statusPublished - 1990

Fingerprint

Calcium Dobesilate
Myocardium
Biomarkers
Myocardial Infarction
Placebos
Glycosaminoglycans
Serum
Myoglobin
MB Form Creatine Kinase
Creatine
Creatine Kinase
Infarction
Isoenzymes
CLS 2210
Necrosis

Keywords

  • Acute myocardial infarction
  • Calcium dobesilate
  • Creatine kinase
  • Glycosaminoglycans
  • Placebo

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Pharmacology

Cite this

@article{dd56e9da3ca441c98adf3f07bd98cdcc,
title = "Calcium dobesilate (CLS 2210) protects the myocardium in early acute myocardial infarction: A preliminary randomized, double-blind, placebo-controlled study of its effects on biochemical markers",
abstract = "To determine the effect of calcium dobesilate CLS 2210) on biochemical markers of acute myocardial nfarction, and thereby assess its action in limiting myocardial necrosis, this compound was administered intravenously by a randomized, double-blind technique to 23 of 41 patients suffering their first infarction. The remaining 18 patients received a placebo. Administration was egun within 3 h of onset of symptoms and continued for 2 h. Before and during treatment, blood samples were aken for measurement of the serum activity of creatine inase and its isoenzyme MB, and the serum and urinary oncentrations of myoglobin and glycosaminoglycans. Serum creatine kinase and serum and urinary myoglobin vere significantly lower in the CLS 2210-treated patients than in the placebo patients throughout the 72 h (p = 0.01, 0.005, and 0.004, respectively). Serum creatine kinase MB and serum glycosaminoglycan in the CLS 2210 patients were initially higher than in the controls, but fell below the control levels between the 40th and 55th hours (p = 0.89 and 0.02, respectively). The glycosaminoglycan urinary concentrations alone were higher in the CLS 2210 group than in the placebo group throughout (p = 0.0005). These findings suggest that CLS 2210 reduces myocardial infarct size in human subjects, as it is already known to do in animals.",
keywords = "Acute myocardial infarction, Calcium dobesilate, Creatine kinase, Glycosaminoglycans, Placebo",
author = "Laszlo Szlavy and I. Repa and Imre Lengyel and Laszlo Lamboy",
year = "1990",
language = "English",
volume = "15",
pages = "89--95",
journal = "Journal of Cardiovascular Pharmacology",
issn = "0160-2446",
publisher = "Lippincott Williams and Wilkins",
number = "1",

}

TY - JOUR

T1 - Calcium dobesilate (CLS 2210) protects the myocardium in early acute myocardial infarction

T2 - A preliminary randomized, double-blind, placebo-controlled study of its effects on biochemical markers

AU - Szlavy, Laszlo

AU - Repa, I.

AU - Lengyel, Imre

AU - Lamboy, Laszlo

PY - 1990

Y1 - 1990

N2 - To determine the effect of calcium dobesilate CLS 2210) on biochemical markers of acute myocardial nfarction, and thereby assess its action in limiting myocardial necrosis, this compound was administered intravenously by a randomized, double-blind technique to 23 of 41 patients suffering their first infarction. The remaining 18 patients received a placebo. Administration was egun within 3 h of onset of symptoms and continued for 2 h. Before and during treatment, blood samples were aken for measurement of the serum activity of creatine inase and its isoenzyme MB, and the serum and urinary oncentrations of myoglobin and glycosaminoglycans. Serum creatine kinase and serum and urinary myoglobin vere significantly lower in the CLS 2210-treated patients than in the placebo patients throughout the 72 h (p = 0.01, 0.005, and 0.004, respectively). Serum creatine kinase MB and serum glycosaminoglycan in the CLS 2210 patients were initially higher than in the controls, but fell below the control levels between the 40th and 55th hours (p = 0.89 and 0.02, respectively). The glycosaminoglycan urinary concentrations alone were higher in the CLS 2210 group than in the placebo group throughout (p = 0.0005). These findings suggest that CLS 2210 reduces myocardial infarct size in human subjects, as it is already known to do in animals.

AB - To determine the effect of calcium dobesilate CLS 2210) on biochemical markers of acute myocardial nfarction, and thereby assess its action in limiting myocardial necrosis, this compound was administered intravenously by a randomized, double-blind technique to 23 of 41 patients suffering their first infarction. The remaining 18 patients received a placebo. Administration was egun within 3 h of onset of symptoms and continued for 2 h. Before and during treatment, blood samples were aken for measurement of the serum activity of creatine inase and its isoenzyme MB, and the serum and urinary oncentrations of myoglobin and glycosaminoglycans. Serum creatine kinase and serum and urinary myoglobin vere significantly lower in the CLS 2210-treated patients than in the placebo patients throughout the 72 h (p = 0.01, 0.005, and 0.004, respectively). Serum creatine kinase MB and serum glycosaminoglycan in the CLS 2210 patients were initially higher than in the controls, but fell below the control levels between the 40th and 55th hours (p = 0.89 and 0.02, respectively). The glycosaminoglycan urinary concentrations alone were higher in the CLS 2210 group than in the placebo group throughout (p = 0.0005). These findings suggest that CLS 2210 reduces myocardial infarct size in human subjects, as it is already known to do in animals.

KW - Acute myocardial infarction

KW - Calcium dobesilate

KW - Creatine kinase

KW - Glycosaminoglycans

KW - Placebo

UR - http://www.scopus.com/inward/record.url?scp=0025117754&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025117754&partnerID=8YFLogxK

M3 - Article

C2 - 1688988

AN - SCOPUS:0025117754

VL - 15

SP - 89

EP - 95

JO - Journal of Cardiovascular Pharmacology

JF - Journal of Cardiovascular Pharmacology

SN - 0160-2446

IS - 1

ER -